Denosumab is a receptor activator of nuclear factor kappa-Β ligand (RANKL) monoclonal antibody that has been increasingly used in patients with advanced CKD and HD patients due to its independence from renal function [3]. Here, TNFSF11 is linked to chronic kidney disease.